Cargando…

The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety

Background: Predictive genetic testing has high impact on cancer prevention for BRCA carriers and passing this information in BRCA families is important. Mostly, this is proband-mediated but this path is defective and denies relatives lifesaving information. Objective: To assess the efficacy/safety...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sermijn, Erica, Delesie, Liesbeth, Deschepper, Ellen, Pauwels, Ingrid, Bonduelle, Maryse, Teugels, Erik, De Grève, Jacques
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803813/ https://www.ncbi.nlm.nih.gov/pubmed/26748927 http://dx.doi.org/10.1007/s10689-015-9854-4

Ejemplares similares

Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families
por: Shahi, Rajendra Bahadur, et al.
Publicado: (2019)

Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families
por: Krajc, Mateja, et al.
Publicado: (2008)

The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population
por: Stegel, Vida, et al.
Publicado: (2011)

Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells
por: Chen, Gang, et al.
Publicado: (2010)

Other cancers in BRCA1 and BRCA2 mutation carriers: implications for counselling and follow up
por: Ponder, B
Publicado: (2000)

Selected aspects of genetic counselling for BRCA1 mutation carriers
por: Gronwald, Jacek
Publicado: (2007)

Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
por: Chen, Gang, et al.
Publicado: (2012)

Correction to: Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
por: Chen, Gang, et al.
Publicado: (2020)

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib
por: Noeparast, Amir, et al.
Publicado: (2016)

Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib
por: Chen, Gang, et al.
Publicado: (2013)

Fertility Counseling in BRCA1/2-Mutated Women with Breast Cancer and Healthy Individuals
por: Kufel-Grabowska, Joanna, et al.
Publicado: (2022)

Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers
por: Vermeij, Joanna, et al.
Publicado: (2008)

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer
por: Noeparast, Amir, et al.
Publicado: (2018)

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer
por: Umelo, Ijeoma, et al.
Publicado: (2015)

High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCA-Mutation Testing without Prior Face-to-Face Genetic Counseling
por: Sie, Aisha S., et al.
Publicado: (2015)

Disparities in BRCA counseling across providers in a diverse population of young breast cancer survivors
por: Reid, Sonya, et al.
Publicado: (2020)

Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer
por: Warner, Ellen
Publicado: (2018)

DNA-testing for BRCA1/2 prior to genetic counselling in patients with breast cancer: design of an intervention study, DNA-direct
por: Sie, Aisha S, et al.
Publicado: (2012)

A Counselling Model for BRCA1/2 Genetic Susceptibility Testing
por: van Oostrom, Iris, et al.
Publicado: (2004)

Haplotype analysis in German families with recurrent BRCA1 and BRCA2 mutations
por: Wappenschmidt, B, et al.
Publicado: (2001)

BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia
por: Tamboom, Kristiina, et al.
Publicado: (2010)

CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition
por: Noeparast, Amir, et al.
Publicado: (2019)

BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families
por: Antoniou, Antonis C, et al.
Publicado: (2006)

Prevalance of BRCA1 and BRCA2 mutations in familial breast cancer patients in Lebanon
por: Jalkh, Nadine, et al.
Publicado: (2012)

Age and Geographical Distribution in Families with BRCA1/BRCA2 Mutations in the Slovak Republic
por: Ciernikova, Sona, et al.
Publicado: (2006)

BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1.
por: Lancaster, J. M., et al.
Publicado: (1998)

Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer
por: Noor, Alfiah, et al.
Publicado: (2018)

Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas
por: Weren, Robbert D.A., et al.
Publicado: (2016)

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
por: Ligtenberg, M J L, et al.
Publicado: (1999)

BRCA1 and BRCA2 Germline Mutations Screening in Algerian Breast/Ovarian Cancer Families
por: Cherbal, Farid, et al.
Publicado: (2010)

Germline Mutations in BRCA1 and BRCA2 in Polish Families Predisposed to Breast and Ovary Cancers
por: Grzybowska, E., et al.
Publicado: (1999)

Novel Germline Mutations of BRCA1 and BRCA2 in Korean Familial Breast Cancer Patients
por: Kim, Hee Nam, et al.
Publicado: (2019)

Five Italian Families with Two Mutations in BRCA Genes
por: Vietri, Maria Teresa, et al.
Publicado: (2020)

Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families
por: Pouliot, Marie-Christine, et al.
Publicado: (2017)

Nipple Sparing Mastectomy as a Risk-Reducing Procedure for BRCA-Mutated Patients
por: Rocco, Nicola, et al.
Publicado: (2021)

Uptake of BRCA1/2 Genetic Testing in a Randomized Trial of Telephone Counseling
por: Butrick, Morgan, et al.
Publicado: (2014)

miR-146a Inhibits Cell Growth, Cell Migration and Induces Apoptosis in Non-Small Cell Lung Cancer Cells
por: Chen, Gang, et al.
Publicado: (2013)

BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients
por: Yazici, H, et al.
Publicado: (2000)

BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families
por: Claes, K, et al.
Publicado: (2004)

Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families
por: Eerola, Hannaleena, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_j481l25t28vb02248cafvhqfnp